Newland Pharmaceutical Co., Ltd. (SHE:301277)

Market Cap	5.81B
Revenue (ttm)	761.64M
Net Income (ttm)	174.28M
Shares Out	392.08M
EPS (ttm)	0.44
PE Ratio	33.43
Forward PE	n/a
Dividend	0.29 (1.93%)
Ex-Dividend Date	Apr 16, 2025

Volume	9,450,248
Average Volume	12,040,970
Open	14.50
Previous Close	14.83
Day's Range	14.50 - 14.87
52-Week Range	8.27 - 18.38
Beta	0.48
RSI	51.84
Earnings Date	Aug 12, 2025

About Newland Pharmaceutical

Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. The company offers pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. It also provides APIs, such as ropivacaine hydrochloride, naphazoline hydrochloride, moxifloxacin hydrochloride, lidocaine hydrochloride, vildagliptin, tadalafil, chlorpheniramine maleate, clopidogrel bisulfate, l...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 1,042
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301277

Financial Performance

In 2024, Newland Pharmaceutical's revenue was 726.44 million, an increase of 11.51% compared to the previous year's 651.44 million. Earnings were 173.63 million, an increase of 9.22%.